PPP metabolites, on the other hand, maintain AKT activity by negatively regulating the expression of its inhibitor PHLDA3. Loss of the PTEN tumor suppressor or activation of the PI3K/AKT pathway in cancer cells enhances G6PD activity and the PPP by inhibiting TRIM21. Here, PHLDA3 is linked to neoplasm.